This compound is a pharmaceutical intermediate specifically used in the manufacturing process of Elagolix. It features a complex structure containing multiple aromatic rings and halogen atoms, serving as a key building block in the synthesis of this active pharmaceutical ingredient.
Alcance del contenido: La información de esta página se refiere a la identificación química y a los contextos de suministro industrial, investigación y producción. No constituye una afirmación terapéutica, un consejo médico ni instrucciones de uso de medicamentos.
¿Adquiriendo o suministrando este compuesto?
Publique su inventario o una solicitud de compra
CAS 832720-84-0
Ethyl (R)-4-((2-(5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-(trifluoromethyl)benzyl)-4-methyl-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl)-1-phenylethyl)amino)butanoate hydrochloride
pharmaceutical intermediate
Elagolix
GnRH antagonist active pharmaceutical ingredient
Elagolix sodium
gonadotropin-releasing hormone antagonist
Carbamic acid, N-[(1R)-2-hydroxy-1-phenylethyl]-, 1,1-dimethylethyl ester
Elagolix intermediate
(1R,5S)-8-Benzyl-8-azabicyclo(3.2.1)octan-3-one hydrochloride
pharmaceutical intermediate
N-(tert-Butoxycarbonyl)-D-prolinol
peptide synthesis intermediate
Methanesulfonic acid [(R)-2,2-dimethyl-[1,3]dioxolan-4-yl]methyl ester
pharmaceutical intermediate
2-Amino-4,5-difluorobenzoic acid
Pharmaceutical intermediate for drug synthesis
ethyl 4-[[(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-4-methyl-2,6-dioxopyrimidin-1-yl]-1-phenylethyl]amino]butanoate
KSJCDYANYVOJPK-MHZLTWQESA-N
CCOC(=O)CCCN[C@@H](CN1C(=O)C(=C(N(C1=O)CC2=C(C=CC=C2F)C(F)(F)F)C)C3=C(C(=CC=C3)OC)F)C4=CC=CC=C4
—